Recombinant human erythropoietin treatment protects the cardio-renal axis in a model of moderate chronic renal failure

REFERENCES

• Deicher R, Hörl WH. Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens. 2003;12:139–143.
   PubMedGoogle Scholar
• Stevens LA, Levin A. Anaemia, cardiovascular disease and kidney disease: Integrating new knowledge in 2002. Curr Opin Nephrol Hypertens. 2003;12:133–138.
   PubMedGoogle Scholar
• Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents – What do we know and what needs to be clarified? Nephrol Dial Transplant. 2005;20:2–7.
   Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anaemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity – The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant. 1998;13: 1642–1644.
   PubMed Web of Science ®Google Scholar
• Silverberg D, Wexler D, Blum M, Wollman Y, Iaina A. The cardio-renal anaemia syndrome: Does it exist? Nephrol Dial Transplant. 2003;18:7–12.
   PubMedGoogle Scholar
• Palazzuoli A, Gallotta M, Iovine F, Nuti R, Silverberg DS. Anaemia in heart failure: A common interaction with renal insufficiency called the cardio-renal anaemia syndrome. Int J Clin Pract. 2008;62:281–286.
   PubMedGoogle Scholar
• Fluck R. Controversies in chronic kidney disease, anaemia and cardiovascular disease. Br J Hosp Med. 2008;69:580–586.
   Google Scholar
• McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. Eur J Clin Invest. 2005;35:58–65.
   PubMedGoogle Scholar
• Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90–95.
   PubMed Web of Science ®Google Scholar
• Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev. 2008;13:415–423.
   PubMed Web of Science ®Google Scholar
• Bogoyevitch MA. An update on the cardiac effects of erythopoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res. 2004;63:208–216.
   PubMed Web of Science ®Google Scholar
• Manolis AS, Tzeis S, Triantafyllou K, Erythropoietin in heart failure and other cardiovascular diseases: Hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:355–375.
   PubMedGoogle Scholar
• Shang Y, Wu Y, Yao S, Wang X, Feng D, Yang W. Protective effect of erythropoietin against ketamine-induced apoptosis in cultured rat cortical neurons: Involvement of PI3K/Akt and GSK-3 beta pathway. Apoptosis. 2007;12:2187–2195.
   PubMed Web of Science ®Google Scholar
• Yang CW, Li C, Jung JY, Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17:1754–1755.
   PubMed Web of Science ®Google Scholar
• Abdelrahman M, Sharples EJ, McDonald MC, Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock. 2004;22:63–69.
   PubMed Web of Science ®Google Scholar
• Ma R, Xiong N, Huang C, Erythropoietin protects PC12 cells from beta-amyloid(25–35)-induced apoptosis via PI3K/Akt signalling pathway. Neuropharmacology. 2009;56: 1027–1034.
   PubMed Web of Science ®Google Scholar
• Garrido P, Reis F, Costa E, Characterization of a rat model of moderate chronic renal failure – Focus on hematological, biochemical and cardio-renal profiles. Ren Fail. 2009; 31:833–842.
   PubMed Web of Science ®Google Scholar
• Reis F, Rocha L, Ponte L, Effect of preventive and regressive isosorbide 5-mononitrate treatment on catecholamine levels in plasma, platelets, adrenals, left ventricle and aorta in cyclosporin A-induced hypertensive rats. Life Sci. 2005;77:2514–2528.
   PubMedGoogle Scholar
• Vandesompele J, De Preter K, Pattyn F, Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:R34.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25:402–408.
   PubMed Web of Science ®Google Scholar
• Weidemann A, Johnson RS. Nonrenal regulation of EPO synthesis. Kidney Int. 2009;75:682–688.
   PubMed Web of Science ®Google Scholar
• Fernandez-Fresnedo G, Rodrigo E, de Francisco AL, de Castro SS, Castañeda O, Arias M. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol. 2006;17:S246–S249.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33:821–828.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538–548.
   PubMed Web of Science ®Google Scholar
• Jie KE, Verhaar MC, Cramer MJ, Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol. 2006;291:F933–F944.
   Google Scholar
• Piloto N, Teixeira HM, Teixeira-Lemos E, Erythropoietin promotes deleterious cardiovascular effects and live risk in a rat model of chronic sports doping. Cardiovasc Toxicol. 2009;9:201–210.
   PubMedGoogle Scholar
• Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol. 2004;15:524–537.
   PubMed Web of Science ®Google Scholar